(Q35544746)

8 August 2017

1 reference

title

An overview of targeted treatments in cancer (English)

1 reference

8 August 2017

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80209-6

14 March 2024

2

Toni Choueiri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512124

14 March 2024

author name string

Rony Abou-Jawde

1

1 reference

8 August 2017

Carlos Alemany

3

1 reference

8 August 2017

Tarek Mekhail

4

1 reference

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14512124

14 March 2024

publication date

1 August 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0149291803802096?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80209-6

https://api.elsevier.com/content/article/PII:S0149291803802096?httpAccept=text/plain

14 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80209-6

14 March 2024

published in

Clinical Therapeutics

1 reference

8 August 2017

25

1 reference

8 August 2017

2121-2137

1 reference

8 August 2017

8

1 reference

Issues on clinical applications of cancer vaccines

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

The unique aspects of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Mapping of the human retinoic acid receptor to the q21 band of chromosome 17

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Differentiation therapy for acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

All-trans-retinoic acid in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Leukemias, myeloma, and other lymphoreticular neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Antibody-targeted immunotherapy for treatment of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Alemtuzumab: a novel monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Role of an anti-epidermal growth factor receptor in treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Epidermal growth factor receptor-targeted therapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Tumor antigens recognized by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980209-6

7 January 2021

Radiolabeled antibody therapy of B-cell lymphomas

25

1 reference

https://api.crossref.org/works/10.1016/S0149-2918(03)80209-6

14 March 2024

Identifiers

1 reference

release_jna4paowebcjrb3xrmnaqr6ovu

8 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jna4paowebcjrb3xrmnaqr6ovu

24 November 2022

mapped directly with Wikidata item

1 reference